GlassScriptPhysician profile
Sherry R Kohn
NPI 1710291034
$2,464.05
in general payments reported to CMS, 2019-2025
22 companies · $1,090 in 2025
The $1,090 reported for 2025 was more than what 86% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $235 · 2022: $126 · 2023: $337 · 2024: $675 · 2025: $1,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,102.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $586.82 | 2024-2025 | Evenity, Prolia, Prolia |
| Novo Nordisk INC | $584.13 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $149.75 | 2021-2022 | |
| Lilly USA, LLC | $135.73 | 2023-2025 | Mounjaro, Zepbound, Taltz |
| Urovant Sciences INC | $124.99 | 2021 | |
| Kyowa Kirin, INC. | $122.74 | 2025 | |
| Alvogen INC | $116.53 | 2024-2025 | Teriparatide |
| Exact Sciences Corporation | $76.46 | 2023-2024 | Cologuard Collection Kit |
| Radius Health, INC. | $75.96 | 2025 | Tymlos, Binosto |
| Corcept Therapeutics | $69.03 | 2025 | Korlym |
| Ascendis Pharma Endocrinology INC | $56.59 | 2025 | Yorvipath |
| Pfizer INC. | $51.85 | 2023-2024 | |
| Glaxosmithkline, LLC. | $46.58 | 2023 | Trelegy Ellipta, Shingrix |
| Neurocrine Biosciences, INC. | $44.80 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $40.44 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $33.16 | 2023 | Arcalyst |
| Alexion Pharmaceuticals, INC. | $32.18 | 2025 | Strensiq |
| Sumitomo Pharma America, INC. | $28.47 | 2024 | Gemtesa |
| Intra-Sana Laboratories | $25.59 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.64 | 2023 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Lexicon Pharmaceuticals, INC. | $22.49 | 2023 | Inpefa |
| Otsuka America Pharmaceutical, INC. | $17.12 | 2024 | Nuedexta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherry Kohn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.